PARP1 and ovarian cancer: Endogenous inhibition of PARP activity through increased levels of NADP+ was shown to render ovarian cancer cells hypersensitive to PARP inhibitors irrespective of the BRCA status, suggesting that NADP+ levels could also be used as a biomarker of PARP inhibitor sensitivity (Bian et al. 2019).